Proficio Capital Partners LLC Has $218,000 Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Proficio Capital Partners LLC lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 99.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 808 shares of the biopharmaceutical company’s stock after selling 192,852 shares during the quarter. Proficio Capital Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $218,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Capital World Investors boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock valued at $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Capital Research Global Investors grew its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Norges Bank bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ALNY shares. Scotiabank raised their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 31st. HC Wainwright reaffirmed a “buy” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $385.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 16th. Finally, Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $347.75.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This represents a 28.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.1%

Shares of Alnylam Pharmaceuticals stock opened at $325.64 on Thursday. The business has a 50 day moving average price of $309.80 and a 200 day moving average price of $273.38. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company has a market capitalization of $42.46 billion, a P/E ratio of -155.81 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. During the same period last year, the company posted ($0.16) earnings per share. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.